Monopar Therapeutics Inc (MNPR NASDAQ) stock market data APIs
$29.6554
0.19(0.6%)
as of March 14, 2025
Monopar Therapeutics Inc Financial Data Overview
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
Prev. Close
29.4653
Open
29.6554
High
31.2543
Low
29.6554
52 wk Range
1.72-54.3
Market Cap
182 M
Shares Outstanding
6 103 K
EPS
-0.37
Beta
1.194
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Monopar Therapeutics Inc data using free add-ons & libraries
Get Monopar Therapeutics Inc Fundamental Data
Monopar Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Monopar Therapeutics Inc News
New
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025
We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where Monopar Therapeutics Inc (NASDAQ:MNPR) stands ag...
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
Penny stocks are risky. That’s why we attach a warning to the tail-end of penny stock articles. It’s also why the SEC warns of their dangers. “Penny stocks may trade infrequently — which mean...
Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treat...
Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to ext...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
